Profile data is unavailable for this security.
About the company
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
- Revenue in USD (TTM)3.82bn
- Net income in USD624.38m
- Incorporated1984
- Employees27.81k
- LocationDr Reddy's Laboratories Ltd8-2-337, Road No.3 Banjara HillsHYDERABAD 500-034IndiaIND
- Phone+91 4 049002900
- Fax+91 4 049002999
- Websitehttps://www.drreddys.com/
More ▼
Mergers & acquisitions
| Acquired company | DRREDDY:NSI since announced | Transaction value |
|---|---|---|
| Janssen Pharmaceutica Nv- Stugeron Portfolio | -0.89% | 50.39m |
Data delayed at least 15 minutes, as of Feb 18 2026 09:59 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals Inc | 174.33m | -197.71m | 6.84bn | 283.00 | -- | 45.94 | -- | 39.25 | -3.10 | -3.10 | 2.74 | 4.43 | 0.4006 | 1.03 | 6.66 | 616,021.20 | -44.19 | -52.46 | -57.53 | -61.22 | 89.40 | -- | -110.32 | -354.18 | 4.53 | -27.83 | 0.2693 | -- | 68.06 | -- | -43.26 | -- | -- | -- |
| Krystal Biotech Inc | 389.13m | 204.83m | 8.35bn | 295.00 | 42.08 | 6.89 | 39.64 | 21.45 | 6.84 | 6.84 | 13.00 | 41.78 | 0.3257 | 0.6882 | 3.35 | 1,319,085.00 | 17.14 | 2.46 | 18.75 | 2.63 | 94.08 | -- | 52.64 | 13.06 | 9.56 | -- | 0.00 | 0.00 | 33.94 | -- | 129.74 | -- | -4.24 | -- |
| Axsome Therapeutics Inc | 561.26m | -229.53m | 9.24bn | 683.00 | -- | 125.08 | -- | 16.46 | -4.67 | -4.67 | 11.40 | 1.47 | 0.9121 | 2.40 | 3.50 | 821,761.40 | -37.30 | -59.62 | -68.09 | -80.32 | 91.86 | -- | -40.89 | -134.06 | 1.50 | -28.27 | 0.7255 | -- | 42.53 | -- | -20.05 | -- | 75.71 | -- |
| Halozyme Therapeutics, Inc. | 1.24bn | 595.49m | 9.46bn | 350.00 | 16.92 | 18.77 | 13.97 | 7.61 | 4.76 | 4.76 | 9.90 | 4.29 | 0.5728 | 1.21 | 3.93 | 3,551,006.00 | 27.45 | 22.20 | 35.10 | 25.70 | 84.55 | 80.85 | 47.91 | 45.39 | 1.37 | -- | 0.7499 | 0.00 | 22.44 | 38.95 | 57.71 | -- | 21.50 | -- |
| Jazz Pharmaceuticals PLC | 4.16bn | -368.48m | 10.21bn | 2.80k | -- | 2.58 | 32.12 | 2.45 | -6.07 | -6.07 | 67.81 | 65.18 | 0.3522 | 0.936 | 5.59 | 1,484,940.00 | -3.12 | 1.36 | -3.62 | 1.50 | 88.49 | 88.18 | -8.85 | 3.98 | 1.44 | 2.17 | 0.5752 | 0.00 | 6.12 | 13.48 | 35.02 | 1.37 | -23.40 | -- |
| Avidity Biosciences Inc | 20.87m | -549.79m | 11.27bn | 391.00 | -- | 5.67 | -- | 540.27 | -4.17 | -4.17 | 0.1589 | 12.85 | 0.0111 | -- | 2.78 | 53,370.84 | -29.13 | -30.46 | -31.29 | -33.14 | -- | -- | -2,634.59 | -1,901.74 | -- | -- | 0.00 | -- | 13.99 | 36.27 | -51.87 | -- | 97.52 | -- |
| Biomarin Pharmaceutical Inc | 3.09bn | 520.42m | 11.52bn | 3.04k | 22.47 | 1.90 | 19.10 | 3.72 | 2.67 | 2.67 | 15.82 | 31.53 | 0.4278 | 0.4512 | 3.95 | 1,017,764.00 | 7.20 | 2.18 | 8.04 | 2.46 | 81.32 | 76.43 | 16.82 | 6.07 | 3.10 | -- | 0.0897 | 0.00 | 17.97 | 10.86 | 154.62 | -- | -9.83 | -- |
| Dr Reddy's Laboratories Ltd (ADR) | 3.82bn | 624.38m | 11.79bn | 27.81k | 19.22 | 2.92 | 14.11 | 3.09 | 0.7492 | 0.7492 | 4.58 | 4.94 | 0.6625 | 1.97 | 3.54 | 137,211.30 | 10.75 | 12.19 | 15.04 | 17.03 | 55.18 | 56.61 | 16.23 | 15.84 | 1.35 | -- | 0.1527 | 14.72 | 16.61 | 13.27 | 1.54 | 23.73 | 41.52 | 9.25 |
| Elanco Animal Health Inc | 4.59bn | 36.00m | 12.35bn | 9.00k | 347.11 | 1.83 | 17.50 | 2.69 | 0.0716 | 0.0716 | 9.23 | 13.58 | 0.3422 | 1.24 | 5.30 | 510,111.10 | 0.2683 | -2.71 | 0.2993 | -3.02 | 54.96 | 54.72 | 0.7841 | -9.52 | 1.23 | 1.30 | 0.3735 | -- | 0.4981 | 7.65 | 127.46 | 37.85 | -3.99 | -- |
| Neurocrine Biosciences Inc | 2.86bn | 478.60m | 12.82bn | 2.00k | 27.40 | 3.93 | 25.21 | 4.48 | 4.66 | 4.66 | 27.91 | 32.50 | 0.6851 | 0.8244 | 4.91 | 1,430,250.00 | 11.46 | 9.00 | 13.48 | 10.78 | 98.18 | 98.32 | 16.73 | 13.51 | 3.30 | -- | 0.00 | -- | 21.45 | 22.29 | 40.23 | 3.28 | 25.55 | -- |
| BridgeBio Pharma Inc | 353.78m | -797.12m | 14.62bn | 725.00 | -- | -- | -- | 41.32 | -4.19 | -4.19 | 1.86 | -10.03 | 0.4254 | -- | -- | 487,972.40 | -96.88 | -75.74 | -125.35 | -94.24 | 95.78 | 96.67 | -227.74 | -716.92 | 3.76 | -2.89 | 3.52 | -- | 2,285.27 | 40.48 | 16.70 | -- | 11.63 | -- |
| Moderna Inc | 1.94bn | -2.82bn | 17.16bn | 5.80k | -- | 1.98 | -- | 8.83 | -7.26 | -7.26 | 5.00 | 22.14 | 0.1468 | 5.34 | 7.17 | -- | -21.31 | 10.19 | -25.32 | 13.43 | 62.91 | 75.16 | -145.16 | 19.02 | 3.22 | -- | 0.0659 | -- | -39.93 | 19.33 | 20.75 | -- | 24.53 | -- |
Data as of Feb 17 2026. Currency figures normalised to Dr Reddy's Laboratories Ltd's reporting currency: US Dollar USD
8.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Robeco Institutional Asset Management BVas of 31 Dec 2025 | 13.15m | 1.58% |
| RBC Global Asset Management (UK) Ltd.as of 30 Sep 2025 | 9.73m | 1.17% |
| Aperio Group LLCas of 31 Dec 2025 | 9.14m | 1.10% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 8.26m | 0.99% |
| Aikya Investment Management Ltd.as of 31 Dec 2025 | 7.34m | 0.88% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 4.84m | 0.58% |
| Parametric Portfolio Associates LLCas of 31 Dec 2025 | 4.70m | 0.56% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 4.29m | 0.51% |
| BNP Paribas Financial Marketsas of 31 Dec 2025 | 4.15m | 0.50% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 3.99m | 0.48% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
